CARET
BehavioralCombined Aerobic and Resistance Exercise Training
NCT Number: NCT02272426
It is estimated that 2 out of 3 patients with a stroke have some problems with their memory, difficulties performing certain tasks, making decisions and learning new things. In addition, many stroke patients do not get regular exercise and are often sedentary. Both physical and cognitive exercise have the potential to improve quality of life, cognition, and overall health, but the safety and tolerability of such interventions is not clear in stroke patients. The investigators will examine these outcomes by allocating stroke survivor participants to one of two groups: a combined exercise and cognitive training program and a sham control group.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Jackson Memorial Hospital, Miami, Florida, United States
Stroke is well recognized as the leading cause of disability in the United States. Cognitive deficits after stroke are common, even in those without dementia prior to the event, and stroke patients with worse cognition on hospital admission have worse outcomes. Cognitive deficits contribute to stroke-related disability and mortality. Evidence suggests an interaction between cognitive deficits and physical limitations, and cognitive rehabilitation may improve functional outcomes post stroke. Recent data also suggest that both cognitive training and exercise interventions improve cognition in stroke patients, but few randomized trials of these interventions, alone or in combination, have been conducted.
We will study the effects of a Combined Aerobic and Resistance Exercise Training (CARET) program and CTI interventions on the primary outcome of safety, feasibility, and adherence among ischemic or hemorrhagic stroke survivors with mild to moderate disability. We hypothesize that these interventions are safe and tolerable, and that they will lead to improvements in our secondary outcomes of cognitive performance and quality of life. We will also explore the role of Brain Derived Neurotrophic Factor in cognitive changes related to the physical exercise intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Combined Aerobic and Resistance Exercise Training
Cognitive Training Intervention
Sham Combined Aerobic and Resistance Exercise Training
Sham Cognitive Training Intervention
Time frame: At 12 weeks visit (post-intervention)
To assess the number of participants with serious adverse events related to the interventions, comparing active groups versus the sham group.
Time frame: At 12 weeks visit (post-intervention)
To assess participant adherence in the intervention group versus the sham group, comparing time on study.
Time frame: Baseline to 6 months follow up
Global cognitive performance will be compared for the intervention groups versus the sham group, using a cognitive assessment battery.
Time frame: Baseline to 6 months follow up measure.
As measured by Center for Epidemiologic Studies Depression Scale (CES-D). Minimum score 0, maximum score 60, and a score of 16 or higher indicates clinical depression.
Time frame: Baseline to 6 months follow up
As measured by Stroke impact scale scores measuring health related quality of life. Minimum score 16, maximum score 80. Higher scores indicate higher level of functionality in participants, while lower scores indicate a lower level of functionality.
Time frame: Baseline to 6 month follow up
Brain-derived neurotrophic factor (BDNF) levels will be compared between the exercise group and the sham group at baseline and 12 weeks.
University of Miami
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07492849
Atrophy, Brain Diseases
Kaohsiung City, Taiwan
View Trial DetailsNCT01796015
Brain Diseases, Cardiovascular Diseases
Bron, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT03685578
Brain Diseases, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05767437
Brain Diseases, Cardiovascular Diseases
Ulsan, Ulju, South Korea
View Trial Details